Phase II Study of Cetuximab in Combination with Docetaxel in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck after Platinum-Containing Therapy: A Multicenter Study of the Arbeitsgemeinschaft Internistische Onkologie-Reference-Cited by-同舟云学术

Phase II Study of Cetuximab in Combination with Docetaxel in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck after Platinum-Containing Therapy: A Multicenter Study of the Arbeitsgemeinschaft Internistische Onkologie

Published:2013 Issue:5 Volume:84 Page:284-289
ISSN:1423-0232
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Knoedler M.,Gauler T.C.,Gruenwald V.,Matzdorff A.,Schroeder M.,Dietz A.,Jordan W.-O.,Arnold D.,Hennemann B.,Hofele C.,Weissinger F.,Eberhardt W.,Keilholz U.

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Reference18 articles.

1. A Retrospective Analysis of the Outcome of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Refractory to a Platinum-based Chemotherapy

2. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody;ESMO Open;2024-06

2. Cetuximab in squamous cell carcinoma of the head and neck;Revisiones en Cáncer;2024

3. Plattenepithelkarzinom des Kopf-Hals-Bereichs: Palliative Systemtherapie;TumorDiagnostik & Therapie;2022-11-25

4. Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study;Oral Oncology;2022-01

5. Head and neck cancer;The Lancet;2021-12